These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 14605329

  • 1. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene.
    Montaner J, Fernández-Cadenas I, Molina CA, Monasterio J, Arenillas JF, Ribó M, Quintana M, Chacón P, Andreu AL, Alvarez-Sabín J.
    Stroke; 2003 Dec; 34(12):2851-5. PubMed ID: 14605329
    [Abstract] [Full Text] [Related]

  • 2. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.
    Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabín J.
    Circulation; 2003 Feb 04; 107(4):598-603. PubMed ID: 12566373
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke.
    Montaner J, Alvarez-Sabín J, Molina CA, Anglés A, Abilleira S, Arenillas J, Monasterio J.
    Stroke; 2001 Dec 01; 32(12):2762-7. PubMed ID: 11739970
    [Abstract] [Full Text] [Related]

  • 4. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.
    Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Dávalos A.
    Stroke; 2004 Jul 01; 35(7):1671-6. PubMed ID: 15166391
    [Abstract] [Full Text] [Related]

  • 5. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
    Tsuruoka A, Atsumi C, Mizukami H, Imai T, Hagiwara Y, Hasegawa Y.
    J Stroke Cerebrovasc Dis; 2014 Jul 01; 23(10):2894-2899. PubMed ID: 25282183
    [Abstract] [Full Text] [Related]

  • 6. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.
    Castellanos M, Sobrino T, Millán M, García M, Arenillas J, Nombela F, Brea D, Perez de la Ossa N, Serena J, Vivancos J, Castillo J, Dávalos A.
    Stroke; 2007 Jun 01; 38(6):1855-9. PubMed ID: 17478737
    [Abstract] [Full Text] [Related]

  • 7. Platelet derived growth factor-CC isoform is associated with hemorrhagic transformation in ischemic stroke patients treated with tissue plasminogen activator.
    Rodríguez-González R, Blanco M, Rodríguez-Yáñez M, Moldes O, Castillo J, Sobrino T.
    Atherosclerosis; 2013 Jan 01; 226(1):165-71. PubMed ID: 23218119
    [Abstract] [Full Text] [Related]

  • 8. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke.
    Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Dávalos A.
    Stroke; 2003 Jan 01; 34(1):40-6. PubMed ID: 12511748
    [Abstract] [Full Text] [Related]

  • 9. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
    Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ.
    Neurology; 2006 May 23; 66(10):1550-5. PubMed ID: 16717217
    [Abstract] [Full Text] [Related]

  • 10. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
    Muhammad S, Planz O, Schwaninger M.
    Cerebrovasc Dis Extra; 2016 May 23; 6(2):50-9. PubMed ID: 27560521
    [Abstract] [Full Text] [Related]

  • 11. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.
    Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Quintana M, Alvarez-Sabín J.
    Stroke; 2004 Sep 23; 35(9):2123-7. PubMed ID: 15243150
    [Abstract] [Full Text] [Related]

  • 12. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke.
    Saposnik G, Fang J, Kapral MK, Tu JV, Mamdani M, Austin P, Johnston SC, Investigators of the Registry of the Canadian Stroke Network (RCSN), Stroke Outcomes Research Canada (SORCan) Working Group.
    Stroke; 2012 May 23; 43(5):1315-22. PubMed ID: 22308252
    [Abstract] [Full Text] [Related]

  • 13. Role of the MMP9 gene in hemorrhagic transformations after tissue-type plasminogen activator treatment in stroke patients.
    Fernández-Cadenas I, Del Río-Espínola A, Carrera C, Domingues-Montanari S, Mendióroz M, Delgado P, Rosell A, Ribó M, Giralt D, Quintana M, Castellanos M, Obach V, Martínez S, Freijo MM, Jiménez-Conde J, Roquer J, Martí-Fábregas J, Molina CA, Alvarez-Sabín J, Montaner J.
    Stroke; 2012 May 23; 43(5):1398-400. PubMed ID: 22496335
    [Abstract] [Full Text] [Related]

  • 14. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study.
    Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, Milne GL, Hubbard J, Lee H, Stevenson E, Lederer M, Furie KL.
    Stroke; 2008 Jan 23; 39(1):100-4. PubMed ID: 18063832
    [Abstract] [Full Text] [Related]

  • 15. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
    Lapergue B, Dang BQ, Desilles JP, Ortiz-Munoz G, Delbosc S, Loyau S, Louedec L, Couraud PO, Mazighi M, Michel JB, Meilhac O, Amarenco P.
    Stroke; 2013 Mar 23; 44(3):699-707. PubMed ID: 23422087
    [Abstract] [Full Text] [Related]

  • 16. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
    Inzitari D, Giusti B, Nencini P, Gori AM, Nesi M, Palumbo V, Piccardi B, Armillis A, Pracucci G, Bono G, Bovi P, Consoli D, Guidotti M, Nucera A, Massaro F, Micieli G, Orlandi G, Perini F, Tassi R, Tola MR, Sessa M, Toni D, Abbate R, MAGIC Study Group.
    Stroke; 2013 Oct 23; 44(10):2901-3. PubMed ID: 23908067
    [Abstract] [Full Text] [Related]

  • 17. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke.
    Millan M, Sobrino T, Castellanos M, Nombela F, Arenillas JF, Riva E, Cristobo I, García MM, Vivancos J, Serena J, Moro MA, Castillo J, Dávalos A.
    Stroke; 2007 Jan 23; 38(1):90-5. PubMed ID: 17138950
    [Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer.
    Rahimi Z, Yari K, Rahimi Z.
    Asian Pac J Cancer Prev; 2015 Jan 23; 16(3):1175-9. PubMed ID: 25735351
    [Abstract] [Full Text] [Related]

  • 19. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.
    Cocho D, Borrell M, Martí-Fàbregas J, Montaner J, Castellanos M, Bravo Y, Molina-Porcel L, Belvís R, Díaz-Manera JA, Martínez-Domeño A, Martínez-Lage M, Millán M, Fontcuberta J, Martí-Vilalta JL.
    Stroke; 2006 Apr 23; 37(4):996-9. PubMed ID: 16497981
    [Abstract] [Full Text] [Related]

  • 20. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry.
    Dzialowski I, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD, CASES Investigators.
    Stroke; 2007 Jan 23; 38(1):75-9. PubMed ID: 17122437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.